Effect of Aidi injection combined with oxaliplatin and docetaxel in treatment of advanced non-small cell lung cancer

Objective To explore the short and long term efficacy and clinical safety of Aidi injection combined with oxaliplatin(L-OHP) and docetaxel(DXL) in treatment of advanced non-small cell lung cancer(NSCLC).Methods Selected91 patients from September 2009 to August 2010 with NSCLC,they were randomly divided into single-blind observation group(47 cases) and control group(44 cases).The control group using L-OHP + DXL 4 cycles of chemotherapy,observation group added Aidi intravenous injection,50 ml/ d,in 14 d,same cycles as control group,three months after the end of chemotherapy,two groups were compared the efficacy and quality of life,36 months after the therapy,long-term survival comparison were performed between the two groups.Results(1)3 months after the end of chemotherapy,the observation group and the control group patients' overall response rate was 72.3%and 52.3%,respectively,KPS quality of life score was(81.4±5.4)points,and(78.7±5.7) points,respectively,the differences were statistically significant(P 0.05).(2) The observation group and the control group during chemotherapy overall incidence of toxicities are as follows,gastrointestinal reactions,neutropenia,thrombocytopenia,peripheral neurotoxicity,liver damage,kidney damage,skin rash,two groups' toxicity level constitute revealed no significant difference(P 0.05).(3) 36 months after the end of chemotherapy,in the observation group and the control group,the average survival time was 31.030(95%CI 30.752-31.308) months,28.884(95%CI28.609-29.459) months,the cumulative probability of survival was(0.232±0.011),(0.088±0.008),showed a statistically significant difference(P 0.01).Conclusion Aidi injection combined with L-OHP + DXL regimen in treatment of advanced NSCLC could significantly improve the recent efficiency,prolong survival duration after chemotherapy,and show good clinical safety.